Monoclonal and chimeric antibodies specific for human tumor necrosis factor
CA 2106299 C · Owner: Vilcek, Jan · Inventors: Le, Junming; Vilcek, Jan; Siegel, Scott A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo diagnosis and therapy of a number of TN Fu-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies methods of producing the antibody, methods of use of the anti-TNF antibody or , fragment, region or derivative thereof in immunoassays and immunotherapeutic approaches are provided,
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 18, 1992 and granted February 6, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 18, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 18, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.